Meeting
2022 ASCO Annual Meeting
Impact of age and gender on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC): Subgroup analysis of the PANAMA-study (AIO-KRK-0212).
Authors
Kathrin Heinrich
Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, München, Germany, Munich, Germany
Kathrin Heinrich , Meinolf Karthaus , Stefan Fruehauf , Ullrich Graeven , Lothar Müller , Alexander Koenig , Ludwig von Weikersthal , Karel Caca , Albrecht Kretzschmar , Eray Goekkurt , Siegfried Haas , Annabel Helga Sophie Alig , Annika Kurreck , Arndt Stahler , Swantje Held , Anke C. Reinacher-Schick , Volker Heinemann , Sebastian Stintzing , Tanja Trarbach , Dominik Paul Modest
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT01991873
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3567)
DOI
10.1200/JCO.2022.40.16_suppl.3567
Abstract #
3567
Poster Bd #
361
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
PARADIGM study: A multicenter, randomized, phase III study of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer.
First Author: Takayuki Yoshino
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase II study of the safety and efficacy of discontinuing pegfilgrastim for pancreatic adenocarcinoma treated with FOLFIRINOX.
First Author: Masahiro Yanagi
Poster
2024 ASCO Gastrointestinal Cancers Symposium
HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer (mCRC) refractory to anti-EGFR antibodies.
First Author: Atsushi Ishiguro
Poster
2023 ASCO Annual Meeting
A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.
First Author: Hideaki Bando